OA13012A - Method for the prevention of malaria. - Google Patents
Method for the prevention of malaria. Download PDFInfo
- Publication number
- OA13012A OA13012A OA1200500157A OA1200500157A OA13012A OA 13012 A OA13012 A OA 13012A OA 1200500157 A OA1200500157 A OA 1200500157A OA 1200500157 A OA1200500157 A OA 1200500157A OA 13012 A OA13012 A OA 13012A
- Authority
- OA
- OAPI
- Prior art keywords
- sporozoites
- plasmodium
- vaccine
- host
- pharmaceutical composition
- Prior art date
Links
- 201000004792 malaria Diseases 0.000 title claims abstract description 43
- 238000000034 method Methods 0.000 title claims abstract description 38
- 230000002265 prevention Effects 0.000 title description 2
- 210000003046 sporozoite Anatomy 0.000 claims abstract description 178
- 230000002238 attenuated effect Effects 0.000 claims abstract description 49
- 238000011081 inoculation Methods 0.000 claims abstract description 10
- 238000007920 subcutaneous administration Methods 0.000 claims abstract description 10
- 229960005486 vaccine Drugs 0.000 claims description 74
- 244000045947 parasite Species 0.000 claims description 47
- 208000015181 infectious disease Diseases 0.000 claims description 37
- 241000223960 Plasmodium falciparum Species 0.000 claims description 26
- 238000001990 intravenous administration Methods 0.000 claims description 26
- 210000003079 salivary gland Anatomy 0.000 claims description 19
- 241000224016 Plasmodium Species 0.000 claims description 16
- 238000011161 development Methods 0.000 claims description 15
- 230000028993 immune response Effects 0.000 claims description 14
- 241000282414 Homo sapiens Species 0.000 claims description 12
- 210000004027 cell Anatomy 0.000 claims description 10
- 230000005855 radiation Effects 0.000 claims description 10
- 230000002458 infectious effect Effects 0.000 claims description 9
- 241000894007 species Species 0.000 claims description 8
- 230000002440 hepatic effect Effects 0.000 claims description 7
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 238000002255 vaccination Methods 0.000 claims description 4
- 241000256186 Anopheles <genus> Species 0.000 claims description 3
- 241000223801 Plasmodium knowlesi Species 0.000 claims description 3
- 241000223821 Plasmodium malariae Species 0.000 claims description 3
- 241001505293 Plasmodium ovale Species 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- 108010041986 DNA Vaccines Proteins 0.000 claims description 2
- 229940021995 DNA vaccine Drugs 0.000 claims description 2
- 229940022005 RNA vaccine Drugs 0.000 claims description 2
- 108700021021 mRNA Vaccine Proteins 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 244000052769 pathogen Species 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 210000003494 hepatocyte Anatomy 0.000 claims 6
- 230000007170 pathology Effects 0.000 claims 3
- 241000223810 Plasmodium vivax Species 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 229940118768 plasmodium malariae Drugs 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 230000010558 Gene Alterations Effects 0.000 claims 1
- 230000002500 effect on skin Effects 0.000 claims 1
- 238000010353 genetic engineering Methods 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 230000003387 muscular Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 abstract description 20
- 230000001681 protective effect Effects 0.000 description 32
- 241000699670 Mus sp. Species 0.000 description 30
- 241000255925 Diptera Species 0.000 description 28
- 241000282412 Homo Species 0.000 description 28
- 230000003053 immunization Effects 0.000 description 27
- 241000223830 Plasmodium yoelii Species 0.000 description 25
- 238000002649 immunization Methods 0.000 description 20
- 230000036039 immunity Effects 0.000 description 15
- 241000224017 Plasmodium berghei Species 0.000 description 13
- 238000011725 BALB/c mouse Methods 0.000 description 12
- 238000000432 density-gradient centrifugation Methods 0.000 description 12
- 238000002224 dissection Methods 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 229940124735 malaria vaccine Drugs 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000010253 intravenous injection Methods 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 241000283984 Rodentia Species 0.000 description 7
- 206010035500 Plasmodium falciparum infection Diseases 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000001524 infective effect Effects 0.000 description 5
- 208000002476 Falciparum Malaria Diseases 0.000 description 4
- 201000011336 Plasmodium falciparum malaria Diseases 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 210000003936 merozoite Anatomy 0.000 description 4
- 238000013296 A/J mouse Methods 0.000 description 3
- 102100027211 Albumin Human genes 0.000 description 3
- 206010003399 Arthropod bite Diseases 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229940023143 protein vaccine Drugs 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 229940031626 subunit vaccine Drugs 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 101710117490 Circumsporozoite protein Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000008076 immune mechanism Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- 241001414900 Anopheles stephensi Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000337007 Oceania Species 0.000 description 1
- 206010035501 Plasmodium malariae infection Diseases 0.000 description 1
- 206010035502 Plasmodium ovale infection Diseases 0.000 description 1
- 241001442539 Plasmodium sp. Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- XMQFTWRPUQYINF-UHFFFAOYSA-N bensulfuron-methyl Chemical compound COC(=O)C1=CC=CC=C1CS(=O)(=O)NC(=O)NC1=NC(OC)=CC(OC)=N1 XMQFTWRPUQYINF-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 229960002348 hepatitis b surface antigen vaccine Drugs 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 230000008336 microcirculatory blood flow Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 208000018299 prostration Diseases 0.000 description 1
- 244000000040 protozoan parasite Species 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229940126583 recombinant protein vaccine Drugs 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000037369 susceptibility to malaria Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42791102P | 2002-11-20 | 2002-11-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA13012A true OA13012A (en) | 2006-11-10 |
Family
ID=32326611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| OA1200500157A OA13012A (en) | 2002-11-20 | 2003-11-20 | Method for the prevention of malaria. |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1563301B1 (de) |
| JP (1) | JP2006508988A (de) |
| KR (1) | KR20050083941A (de) |
| CN (1) | CN1934448B (de) |
| AP (1) | AP1925A (de) |
| AT (1) | ATE524735T1 (de) |
| AU (1) | AU2003294482A1 (de) |
| BR (1) | BR0316423A (de) |
| CA (1) | CA2506696C (de) |
| ES (1) | ES2371066T3 (de) |
| IL (1) | IL168651A (de) |
| NZ (1) | NZ540719A (de) |
| OA (1) | OA13012A (de) |
| WO (1) | WO2004045559A2 (de) |
| ZA (1) | ZA200504053B (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0417762A8 (pt) | 2003-12-19 | 2015-12-22 | Seattle Biomedical Res Institute | Organismo vivo, um plasmodium, método para inocular um hospedeiro vertebrado contra malária, composição de vacina, uso de um organismo vivo, um plasmodium, e, método de produção de uma composição de vacina |
| US7722860B2 (en) | 2004-12-03 | 2010-05-25 | Seattle Biomedical Research Institute | Live genetically engineered protozoan vaccine |
| US8153116B2 (en) | 2006-07-11 | 2012-04-10 | University Of Connecticut | Use of conditional plasmodium strains lacking an essential gene in malaria vaccination |
| US8128921B2 (en) * | 2006-07-11 | 2012-03-06 | University Of Connecticut | Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination |
| WO2012088605A1 (en) * | 2010-12-27 | 2012-07-05 | Lee Eng Hong | Roadmap for controlling malaria |
| FR2978048B1 (fr) | 2011-07-20 | 2014-10-10 | Univ Paris Curie | Composition vaccinale contre le paludisme |
| AU2015252843B2 (en) * | 2014-05-02 | 2020-12-24 | Sanaria Inc. | Infectious Plasmodium sporozoites grown in vitro |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2031468A1 (en) * | 1989-12-08 | 1991-06-09 | Mitchell S. Gross | Malaria vaccine |
| US5766597A (en) * | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Malaria recombinant poxviruses |
| CZ292475B6 (cs) * | 1999-02-18 | 2003-09-17 | Rmf Dictagene S.A. | Vakcína proti malárii a polypeptid |
| US8735329B2 (en) * | 2008-01-18 | 2014-05-27 | Katholieke Universiteit Leuven K.U. Leuven R&D | Markers and diagnostic methods for metastasis |
-
2003
- 2003-11-20 OA OA1200500157A patent/OA13012A/en unknown
- 2003-11-20 BR BR0316423-3A patent/BR0316423A/pt not_active IP Right Cessation
- 2003-11-20 WO PCT/US2003/037498 patent/WO2004045559A2/en not_active Ceased
- 2003-11-20 CN CN2003801075999A patent/CN1934448B/zh not_active Expired - Fee Related
- 2003-11-20 CA CA2506696A patent/CA2506696C/en not_active Expired - Fee Related
- 2003-11-20 AU AU2003294482A patent/AU2003294482A1/en not_active Abandoned
- 2003-11-20 AP AP2005003332A patent/AP1925A/xx active
- 2003-11-20 NZ NZ540719A patent/NZ540719A/en not_active IP Right Cessation
- 2003-11-20 AT AT03789967T patent/ATE524735T1/de not_active IP Right Cessation
- 2003-11-20 ES ES03789967T patent/ES2371066T3/es not_active Expired - Lifetime
- 2003-11-20 JP JP2004554018A patent/JP2006508988A/ja active Pending
- 2003-11-20 KR KR1020057009184A patent/KR20050083941A/ko not_active Ceased
- 2003-11-20 EP EP03789967A patent/EP1563301B1/de not_active Expired - Lifetime
-
2005
- 2005-05-18 IL IL168651A patent/IL168651A/en active IP Right Grant
- 2005-05-19 ZA ZA200504053A patent/ZA200504053B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1563301A4 (de) | 2007-07-11 |
| WO2004045559A2 (en) | 2004-06-03 |
| KR20050083941A (ko) | 2005-08-26 |
| ES2371066T3 (es) | 2011-12-27 |
| CA2506696C (en) | 2013-05-14 |
| ZA200504053B (en) | 2006-07-26 |
| EP1563301A2 (de) | 2005-08-17 |
| CN1934448A (zh) | 2007-03-21 |
| AU2003294482A1 (en) | 2004-06-15 |
| AP1925A (en) | 2008-12-08 |
| CN1934448B (zh) | 2012-01-11 |
| WO2004045559A3 (en) | 2004-08-12 |
| HK1075936A1 (en) | 2005-12-30 |
| CA2506696A1 (en) | 2004-06-03 |
| EP1563301B1 (de) | 2011-09-14 |
| IL168651A (en) | 2011-04-28 |
| BR0316423A (pt) | 2005-10-11 |
| NZ540719A (en) | 2009-07-31 |
| ATE524735T1 (de) | 2011-09-15 |
| JP2006508988A (ja) | 2006-03-16 |
| AU2003294482A2 (en) | 2005-08-25 |
| AP2005003332A0 (en) | 2005-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20120156245A1 (en) | Methods for the Prevention of Malaria | |
| Vaughan et al. | Genetically engineered, attenuated whole-cell vaccine approaches for malaria | |
| Scheller et al. | Maintenance of protective immunity against malaria by persistent hepatic parasites derived from irradiated sporozoites. | |
| Thera et al. | Vaccines for malaria: how close are we? | |
| Doolan et al. | DNA-based vaccines against malaria: status and promise of the Multi-Stage Malaria DNA Vaccine Operation | |
| Van Braeckel-Budimir et al. | CD8 T-cell-mediated protection against liver-stage malaria: lessons from a mouse model | |
| Healer et al. | Vaccines to accelerate malaria elimination and eventual eradication | |
| Hassert et al. | Memory CD8+ T cell‐mediated protection against liver‐stage malaria | |
| Mikolajczak et al. | Preerythrocytic malaria vaccine development | |
| García-Basteiro et al. | Approaching the target: the path towards an effective malaria vaccine | |
| Gardner et al. | DNA vaccines against malaria: immunogenicity and protection in a rodent model | |
| Shital et al. | An update on recombinant vaccines against leishmaniasis | |
| US20050220822A1 (en) | Methods for the prevention of malaria | |
| Druilhe et al. | Pre-erythrocytic stage malaria vaccines: time for a change in path | |
| Syaifudin et al. | The feasibility of gamma irradiation for developing malaria vaccine | |
| Borkens | Malaria & mRNA vaccines: A possible salvation from one of the most relevant infectious diseases of the global south | |
| EP1563301B1 (de) | Impfstoff zur vorbeugung gegen malaria | |
| Todryk et al. | Building better T‐cell‐inducing malaria vaccines | |
| Verma et al. | Malaria vaccines: Current developments and immunological insights | |
| Hedstrom et al. | The development of a multivalent DNA vaccine for malaria | |
| Good | Our impasse in developing a malaria vaccine | |
| HK1075936B (en) | Vaccine for the prevention of malaria | |
| Kristoff | Malaria stage-specific vaccine candidates | |
| Serrano‐Coll et al. | Plasmodium and Host Immunity: Evasion Strategies and Advances in Malaria Vaccination | |
| Hoffman et al. | Pre-erythrocytic and asexual erythrocytic stage whole-organism malaria vaccines |